Lapo Alinari, MD, PHD
Academic Title: Assistant Professor
Research Program: Leukemia and Hematologic Malignancies
About Me
More info forI am a board-certified hematologist who specializes in treating cancers that are centered in the lymph nodes. My clinical expertise includes caring for patients with aggressive B-cell non-Hodgkin’s lymphomas as well as Hodgkin’s disease. As a physician-scientist at the OSUCCC – James, I am especially passionate about research and I am continually working to develop more advanced treatments that can give my patients the best quality of life possible. It is an honor to work alongside such an exceptional multidisciplinary team. Their skill and devotion to providing compassionate care is unparalleled, and I am confident that The James is the best place for cancer treatment in the world. We are on the cutting-edge of cancer research and are testing novel therapeutic approaches every day. It is deeply rewarding to see my preclinical research translated into therapies that may offer patients superior care and outcomes. As a member of the Leukemia Research Program at The James, my research centers on identifying therapeutic targets and developing innovative therapies for lymphoma patients. My laboratory research is primarily funded by the National Cancer Institute, and I am the principal investigator on several clinical trials. My work has been patented and published in numerous peer-reviewed journals and I have presented my research at more than a dozen national and international conferences. My role at The James also includes serving as the director of the Leukemia Tissue Bank Shared Resource, a novel program that allows our scientists to better study the cellular and molecular properties of various diseases. The program was designed as a collaborative tool to help scientists explore the causes of cancer and develop more effective therapies, and I am proud to be part of it. I also help educate and train the next generation of physicians and researchers. I am an associate director of the Medical Scientist Training Program at The Ohio State University College of Medicine and an associate professor of Internal Medicine in the Division of Hematology. To remain at the forefront of cancer research and provide the most comprehensive and advanced care to my patients, I stay actively involved with several professional organizations. I am a member of the American Society of Hematology, the American Society of Clinical Oncology, the Lymphoma Research Foundation, and the American Association for Cancer Research.
Clinical Expertise
More info for- Non-Hodgkin Lymphoma
- Hodgkin Lymphoma
Education & Training
More info forFellowship - Hematology & Oncology
- Ohio State University Wexner Medical Center
700 Ackerman Rd, Columbus, OH
Internship - Internal Medicine
- Ohio State University Wexner Medical Center
700 Ackerman Rd, Columbus, OH
Residency - Internal Medicine
- Ohio State University Wexner Medical Center
700 Ackerman Rd, Columbus, OH
Fellowship - Hematology
- S Orsola Malpighi Polyclinic
Via Giuseppe Massarenti, Bologna
Residency - Medical Oncology
- S Orsola Malpighi Polyclinic
Via Giuseppe Massarenti, Bologna
Medical School
- Universita Degli Studi di Firenze
Facolta de Medicina e Chirurgia, 50121 Firenze
Graduate
- Universita Di Bologna Facolta Di Medicina E Chirurgia
Via San Vitale 59, Bologna
- Ohio State University Wexner Medical Center
Academic Office & Contact Information
More info forAcademic Office:
Comprehensive Cancer Center
410 W 12th Ave
Columbus, Ohio 43210-1214Phone:
614-685-9256Email:
alinari.1@osu.eduVideos
More info forPublications
More info forOctober 10, 2024Design, Synthesis, and Biological Evaluation of Selective TBL1X Degraders.
Yang R, Pray B, Alinari L, Li PK, Cheng X
ACS Med Chem Lett
May 1, 2024Prognostic relevance of circulating lymphoma cells at diagnosis in newly diagnosed follicular lymphoma patients.
Annunzio K, Bhatta S, Hanel W, Zhao Q, Owen M, Rosen H, Voorhees TJ, Bond DA, Sawalha Y, Sigmund AM, Alinari L, Baiocchi RA, Maddocks KJ, Jones D, Christian B, Epperla N
Hematol Oncol
March 23, 2024Post-infusion PD-1+CD8+CAR-T cells identify patients responsive to CD19-CAR-T therapy in non-Hodgkin's lymphoma.
Denlinger N, Song NJ, Zhang X, Jeon H, Peterson C, Wang Y, Reynolds K, Bolz R, Miao J, Song C, Wu D, Chan WK, Bezerra ED, Epperla N, Voorhees TJ, Brammer JE, Kittai AS, Bond DA, Sawalha Y, Sigmund AM, Reneau JC, Rubinstein MP, Hanel W, Christian B, Baiocchi RA, Maddocks KJ, Alinari L, Vasu S, de Lima M, Chung D, Jaglowski SM, Li Z, Huang X, Yang Y
Blood Adv
January 9, 2024Resistance to PRMT5-targeted therapy in mantle cell lymphoma.
Long ME, Koirala S, Sloan S, Brown-Burke F, Weigel C, Villagomez L, Corps K, Sharma A, Hout I, Harper M, Helmig-Mason J, Tallada S, Chen Z, Scherle P, Vaddi K, Chen-Kiang S, Di Liberto M, Meydan C, Foox J, Butler D, Mason C, Alinari L, Blaser BW, Baiocchi R
Blood Adv
January 1, 2024Inhibition of SRC-3 as a potential therapeutic strategy for aggressive mantle cell lymphoma.
Bijou I, Liu Y, Lu D, Chen J, Sloan S, Alinari L, Lonard DM, O'Malley BW, Wang M, Wang J
PLoS One
October 2, 2023Resistance to PRMT5 Targeted Therapy in Mantle Cell Lymphoma.
Long ME, Koirala S, Sloan SL, Brown-Burke F, Weigel C, Villagomez L, Corps K, Sharma A, Hout I, Harper M, Helmig-Mason J, Tallada S, Chen Z, Scherle P, Vaddi K, Chen-Kiang S, Di Liberto M, Meydan C, Foox J, Butler D, Mason CE, Alinari L, Blaser BW, Baiocchi RA
Blood Adv
September 22, 2023A novel CAR-T cell product targeting CD74 is an effective therapeutic approach in preclinical mantle cell lymphoma models.
Chan WK, Williams J, Sorathia K, Pray B, Abusaleh K, Bian Z, Sharma A, Hout I, Nishat S, Hanel W, Sloan SL, Yasin A, Denlinger N, Zhang X, Muthusamy N, Vasu S, de Lima M, Yang Y, Baiocchi R, Alinari L
Exp Hematol Oncol
August 19, 2023Exploiting the fibroblast growth factor receptor-1 vulnerability to therapeutically restrict the MYC-EZH2-CDKN1C axis-driven proliferation in Mantle cell lymphoma.
Sircar A, Singh S, Xu-Monette ZY, Coyle KM, Hilton LK, Chavdoula E, Ranganathan P, Jain N, Hanel W, Tsichlis P, Alinari L, Peterson BR, Tao J, Muthusamy N, Baiocchi R, Epperla N, Young KH, Morin R, Sehgal L
Leukemia
June 16, 2023PRMT5 Inhibition Drives Therapeutic Vulnerability to Combination Treatment with BCL-2 Inhibition in Mantle Cell Lymphoma.
Brown-Burke F, Hwang I, Sloan SL, Hinterschied C, Helmig-Mason J, Long ME, Chan WK, Prouty A, Chung JH, Zhang Y, Singh S, Youssef Y, Bhagwat N, Chen Z, Chen-Kiang S, DiLiberto M, Elemento O, Sehgal L, Alinari L, Vaddi K, Scherle P, Lapalombella R, Paik J, Baiocchi RA
Blood Adv
June 3, 2023Follicular Helper and Regulatory T Cells Drive the Development of Spontaneous Epstein-Barr Virus Lymphoproliferative Disorder.
Ahmed EH, Lustberg M, Hale C, Sloan S, Mao C, Zhang X, Ozer HG, Schlotter S, Smith PL, Jeney F, Chan WK, Harrington BK, Weigel C, Brooks E, Klimaszewski HL, Oakes CC, Abebe T, Ibrahim ME, Alinari L, Behbehani GK, Shindiapina P, Caligiuri MA, Baiocchi RA
Cancers (Basel)
June 2, 2023PRMT5 supports multiple oncogenic pathways in mantle cell lymphoma.
Sloan SL, Brown F, Long ME, Weigel C, Koirala S, Chung JH, Pray B, Villagomez L, Hinterschied C, Sircar A, Helmig-Mason J, Prouty A, Brooks E, Youssef Y, Hanel W, Parekh S, Chan WK, Chen Z, Lapalombella R, Sehgal L, Vaddi K, Scherle P, Chen-Kiang S, Di Liberto M, Elemento O, Meydan C, Foox J, Butler D, Mason CE, Baiocchi RA, Alinari L
Blood
February 24, 2023A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma.
Hanel W, Shindiapina P, Bond DA, Sawalha Y, Epperla N, Voorhees T, Welkie RL, Huang Y, Behbehani GK, Zhang X, McLaughlin E, Chan WK, Brammer JE, Jaglowski S, Reneau JC, Christian BA, William BM, Cohen JB, Baiocchi RA, Maddocks K, Blum KA, Alinari L
Cancers (Basel)
January 6, 2023Dysregulation of PRMT5 in chronic lymphocytic leukemia promotes progression with high risk of Richter's transformation.
Hing ZA, Walker JS, Whipp EC, Brinton L, Cannon M, Zhang P, Sher S, Cempre CB, Brown F, Smith PL, Agostinelli C, Pileri SA, Skinner JN, Williams K, Phillips H, Shaffer J, Beaver LP, Pan A, Shin K, Gregory CT, Ozer GH, Yilmaz SA, Harrington BK, Lehman AM, Yu L, Coppola V, Yan P, Scherle P, Wang M, Pitis P, Xu C, Vaddi K, Chen-Kiang S, Woyach J, Blachly JS, Alinari L, Yang Y, Byrd JC, Baiocchi RA, Blaser BW, Lapalombella R
Nat Commun
November 14, 2022VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemia.
Sher S, Whipp E, Walker J, Zhang P, Beaver L, Williams K, Orwick S, Ravikrishnan J, Walker B, Perry E, Gregory C, Purcell M, Pan A, Yan P, Alinari L, Johnson AJ, Frigault MM, Greer JM, Hamdy A, Izumi R, Mo X, Sampath D, Woyach J, Blachly J, Byrd JC, Lapalombella R
Leukemia
October 26, 2022Treatment of primary mediastinal B-cell lymphoma with dose-adjusted REPOCH during pregnancy.
Annunzio K, Cackovic M, Bond DA, Sawalha Y, Voorhees TJ, Hanel W, Alinari L, Baiocchi RA, Reneau JC, Brammer JE, Maddocks K, Christian B, Epperla N
Blood Adv
October 25, 2022A FOXO1-dependent transcription network is a targetable vulnerability of mantle cell lymphomas.
Jang JY, Hwang I, Pan H, Yao J, Alinari L, Imada E, Zanettini C, Kluk M, Wang Y, Lee YK, Lin HV, Huang X, Di Liberto M, Chen Z, Ballman KV, Cantley LC, Marchionni L, Inghirami G, Elemento O, Baiocchi R, Chen-Kiang S, Belvedere S, Zheng H, Paik J
J Clin Invest
October 4, 2022TBL1X: AT THE CROSSROADS OF TRANSCRIPTIONAL AND POST-TRANSCRIPTIONAL REGULATION.
Pray BA, Youssef Y, Alinari L
Exp Hematol
September 16, 2022Targeting OXPHOS de novo purine synthesis as the nexus of FLT3 inhibitor-mediated synergistic antileukemic actions.
Zhang P, Brinton LT, Gharghabi M, Sher S, Williams K, Cannon M, Walker JS, Canfield D, Beaver L, Cempre CB, Phillips H, Chen X, Yan P, Lehman A, Scherle P, Wang M, Vaddi K, Baiocchi R, Wang R, Sampath D, Alinari L, Blachly JS, Lapalombella R
Sci Adv
July 13, 2022A sumoylation program is essential for maintaining the mitotic fidelity in proliferating mantle cell lymphoma cells.
Hanel W, Lata P, Youssef Y, Tran H, Tsyba L, Sehgal L, Blaser BW, Huszar D, Helmig-Mason J, Zhang L, Schrock MS, Summers MK, Chan WK, Prouty A, Mundy-Bosse BL, Chen-Kiang S, Danilov AV, Maddocks K, Baiocchi RA, Alinari L
Exp Hematol Oncol
January 1, 2022Outcomes of patients with diffuse large B-cell and high-grade B-cell lymphomas with synchronous CNS and systemic involvement at diagnosis treated with high-dose methotrexate and R-CHOP: a single-center retrospective study.
Fleming M, Huang Y, Dotson E, Bond DA, Reneau J, Epperla N, Alinari L, Brammer J, Christian B, Baiocchi RA, Maddocks K, Sawalha Y
Ther Adv Hematol
November 17, 2021Feasibility of High-dose Methotrexate Administered on Day 1 of (R)CHOP in aggressive non-Hodgkin Lymphomas.
Fleming MK, Huang Y, Dotson EK, Bond DA, Reneau JC, Epperla N, Alinari L, Brammer JE, Christian B, Baiocchi RA, Maddocks K, Sawalha Y
Blood Adv
June 22, 2021SOX11 inhibitors are cytotoxic in mantle cell lymphoma.
Jatiani SS, Christie S, Leshchenko VV, Jain R, Kapoor A, Bisignano P, Lee C, Kaniskan HU, Edwards D, Meng F, Laganà A, Youssef Y, Wiestner A, Alinari L, Jin J, Filizola M, Aggarwal A, Parekh SS
Clin Cancer Res
May 26, 2021Targeted Delivery of BZLF1 to DEC205 Drives EBV-Protective Immunity in a Spontaneous Model of EBV-Driven Lymphoproliferative Disease.
Ahmed EH, Brooks E, Sloan S, Schlotter S, Jeney F, Hale C, Mao C, Zhang X, McLaughlin E, Shindiapina P, Shire S, Das M, Prouty A, Lozanski G, Mamuye AT, Abebe T, Alinari L, Caligiuri MA, Baiocchi RA
Vaccines (Basel)
April 29, 2021Integration of Metabolomics and Gene Expression Profiling Elucidates IL4I1 as Modulator of Ibrutinib Resistance in ABC-Diffuse Large B Cell Lymphoma.
Choueiry F, Singh S, Sircar A, Laliotis G, Sun X, Chavdoula E, Zhang S, Helmig-Mason J, Hart A, Epperla N, Tsichlis P, Baiocchi R, Alinari L, Zhu J, Sehgal L
Cancers (Basel)
February 24, 2021Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL.
Chen TL, Harrington B, Truxall J, Wasmuth R, Prouty A, Sloan S, Lehman AM, Sampath D, Orlemans E, Baiocchi RA, Alinari L, Byrd JC, Woyach JA, Hertlein E
J Hematol Oncol
February 4, 2021Targeting DNA damage repair functions of two histone deacetylases, HDAC8 and SIRT6, sensitizes acute myeloid leukemia to NAMPT inhibition.
Zhang P, Brinton LT, Williams K, Sher S, Orwick S, Lai TH, Mims AS, Coss CC, Kulp SK, Youssef Y, Chan WK, Mitchell S, Mustonen A, Cannon M, Phillips H, Lehman AM, Kauffman T, Beaver L, Canfield D, Grieselhuber NR, Alinari L, Sampath D, Yan P, Byrd JC, Blachly JS, Lapalombella R
Clin Cancer Res
January 1, 2021Validation of protein arginine methyltransferase 5 (PRMT5) as a candidate therapeutic target in the spontaneous canine model of non-Hodgkin lymphoma.
Sloan SL, Renaldo KA, Long M, Chung JH, Courtney LE, Shilo K, Youssef Y, Schlotter S, Brown F, Klamer BG, Zhang X, Yilmaz AS, Ozer HG, Valli VE, Vaddi K, Scherle P, Alinari L, Kisseberth WC, Baiocchi RA
PLoS One
November 4, 2020XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53.
Deng M, Zhang M, Xu-Monette ZY, Pham LV, Tzankov A, Visco C, Fang X, Bhagat G, Zhu F, Dybkaer K, Chiu A, Tam W, Zu Y, Hsi ED, Choi WWL, Huh J, Ponzoni M, Ferreri AJM, Møller MB, Parsons BM, van Krieken JH, Piris MA, Winter JN, Hagemeister F, Alinari L, Li Y, Andreeff M, Xu B, Young KH
J Hematol Oncol
September 22, 2020Targeting phosphatidylinositol 3 kinase-β and -δ for Bruton tyrosine kinase resistance in diffuse large B-cell lymphoma.
Jain N, Singh S, Laliotis G, Hart A, Muhowski E, Kupcova K, Chrbolkova T, Khashab T, Chowdhury SM, Sircar A, Shirazi F, Singh RK, Alinari L, Zhu J, Havranek O, Tsichlis P, Woyach J, Baiocchi R, Samaniego F, Sehgal L
Blood Adv
September 14, 2020Transducin β-like protein 1 controls multiple oncogenic networks in diffuse large B-cell lymphoma.
Youssef Y, Karkhanis V, Chan WK, Jeney F, Canella A, Zhang X, Sloan S, Prouty A, Helmig-Mason J, Tsyba L, Hanel W, Zheng X, Zhang P, Chung JH, Lucas DM, Kauffman Z, Larkin K, Strohecker AM, Ozer HG, Lapalombella R, Zhou H, Xu-Monette ZY, Young KH, Han R, Nurmemmedov E, Nuovo G, Maddocks K, Byrd JC, Baiocchi RA, Alinari L
Haematologica
Consulting and Related Relationships
More info forAt The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the university requires annual disclosures from all faculty members with external interests related to their university responsibilities. As of 09/30/2024, Dr. Alinari has reported relationships with the companies or entities listed below. If you have questions about the relationships listed below, please ask the faculty member. If you have questions about how these relationships are monitored by The Ohio State University Wexner Medical Center, please contact our Compliance Office.
- The Dedham Group